EU MDR translation requirements determine which medical device documents must be translated, into which languages, and when those translations must be available. Under the regulation, manufacturers are responsible for ensuring that instructions for use (IFUs), labels, safety information and clinical documentation are provided in the official language or languages required by each EU member state where the device is sold.

The global medical devices market was valued at around and is expected to exceed USD 1000 billion by 2034. Europe remains central to that growth, accounting for more than and ranking as the second-largest market worldwide after the United States.

Since the EU Medical Device Regulation (MDR) became fully applicable in May 2021, language requirements have become clearer, stricter and more closely enforced. By 2026, with the progressive rollout of EUDAMED and increased scrutiny from notified bodies, translation is no longer an administrative afterthought, but a compliance requirement.

If you manufacture or distribute medical devices in Europe, this guide explains what the EU MDR translation requirements mean in practice, and how to stay compliant without slowing down your market entry.

Europe remains a high-value medical device market

Europe鈥檚 medical technology market was estimated at around and has shown steady long-term growth despite economic uncertainty. Healthcare spending across Europe averages around , with close to 8% of this healthcare spending allocated to medical technology, including medical devices.

Innovation remains strong. Of the more than 15,700 medical-related patents filed with the , over 40% originate from EU and EEA countries, with the US and other regions making up the rest.

Germany and the Netherlands consistently rank among the world鈥檚 largest importers of medical devices, making Europe both a centre of innovation and a highly attractive destination for global manufacturers.

The opportunity is clear, but so are the regulatory expectations.

What the EU MDR covers

The governs 鈥渢he placing on the market, making available on the market or putting into service of medical devices for human use and accessories for such devices鈥� within the European Union.

The most notable difference between this regulation and the directives it replaces is the scope. The MDR now covers:

• Medical devices and accessories
• Certain products without an intended medical purpose but with similar risk profiles
• Software used for medical purposes
• Clinical investigations conducted in the EU

It also covers 鈥淒evices with both a medical and a non-medical intended purpose鈥�, but excludes 鈥渋n vitro diagnostic medical devices covered by Regulation (EU) 2017/746鈥� as well as certain medicinal products such as blood, tissue or anything of animal or human origin.

The practical result is more documentation, more oversight and more content that must be translated correctly.

EU MDR language requirements: Clarity, not choice

One of the most important changes introduced by the MDR is how explicitly it addresses language. The previous regulation says that member states 鈥渕ay require鈥� translations to be made into the various languages of the member states, but in MDR, Chapter IV, Article 41, under the heading 鈥淟anguage requirements鈥�, it says:

鈥淎ll documents required pursuant to Articles 38 and 39 shall be drawn up in a language or languages which shall be determined by the Member State concerned.鈥�

Note the subtle but distinct evolution from 鈥渕ay require鈥� to 鈥渟hall be鈥�. In other words, this is not optional, and producers and resellers should not wait for a request to be made.

Article 41 states that all required documentation must be drawn up in the language or languages determined by the member state concerned. In addition, Annex II requires that labels, packaging and instructions for use (IFUs) be provided in the languages accepted in the member states where the device is sold.

For clinical investigations, Annex XV specifies that summaries must be available in an official EU language determined by the relevant member state.

In short, the responsibility now sits firmly with you to:

• Identify language requirements per country
• Prepare compliant translations in advance
• Maintain consistency across all markets

from the European Commission is useful, as it includes tables you can consult to determine which languages you must cover.

Which documents need to be translated under the MDR?

Depending on your device and its classification, the MDR typically requires translation of:

• Labels and packaging (including transport packaging where relevant)
• Instructions for use (IFUs)
• Safety information, warnings and notices
• Declarations of conformity
• Summaries of Safety and Clinical Performance (SSCPs), where applicable
• Clinical investigation documentation and summaries

There is no single EU language rule. Some countries accept English for certain documents, others do not. Multilingual countries may require translations into all official languages.

EUDAMED and terminology consistency in 2026

The has moved from delayed implementation to progressive operational use across its core modules. By May 28, 2026, the first four modules will be mandatory for new devices, and the deadline for legacy devices is November 28.

These modules are:

• Actor registration
• UDI/Devices registration
• Notified Bodies & certificates
• Market surveillance

From a language perspective, this increases the importance of standardised terminology. MDR requires alignment with internationally recognised medical device nomenclature, and inconsistencies between IFUs, labels, technical documentation and database entries are easier to spot.

This makes terminology management, approved glossaries and reusable translation assets essential for long-term compliance.

MDR, Brexit and selling into the EU

The EU MDR does not apply in Great Britain, where medical devices are regulated under the UK MDR 2002 and overseen by the MHRA. However, the EU MDR continues to apply in Northern Ireland.

If you sell into both the UK and EU:

• UK documentation must be in English
• EU documentation must meet member-state-specific language requirements

For UK-based manufacturers exporting to the EU, MDR-compliant translation workflows remain a business necessity.

Why speed and accuracy matter equally

MDR documentation must be available at the point of market entry, which means that translations need to be ready when you submit technical documentation, not afterwards.

At the same time, accuracy is critical. A showed how an incorrect translation of 鈥渘on-modular cemented鈥� as 鈥渨ithout cement鈥� led to dozens of knee implants being applied incorrectly. The issue was not regulation 鈥� it was translation quality.

Poor translation can:

• Delay CE marking
• Trigger regulatory questions
• Increase liability risk
• Compromise patient safety

This is why many manufacturers work with specialist medical device translation services that understand MDR, clinical terminology and regulatory expectations.

Consistency supports compliance and efficiency

As MDR enforcement matures and EUDAMED use increases, consistency across languages becomes easier to audit and harder to overlook.

Using controlled terminology, validated glossaries and translation memory tools helps you:

• Maintain consistency across documents and markets
• Reduce review cycles
• Improve turnaround times
• Lower long-term translation costs

These resources can then be reapplied to subsequent translations, thus saving turnaround time without sacrificing accuracy or introducing inconsistencies. When managed correctly, quality and speed do not have to compete.

Supporting compliance and a healthy bottom line

Europe remains a high-value market for medical devices, but access depends on meeting clear regulatory and linguistic requirements. The MDR aims to reduce ambiguity, protect patients and improve transparency 鈥� and language plays a central role in that goal.

By ensuring your documentation is translated accurately, consistently and in line with member-state requirements, you protect patients, support compliance and keep your products moving to market.

Working with an experienced language partner helps you do all three without unnecessary friction. Read more about our medical translation services here.